At its ongoing genomics forum, narrow-moat Illumina finally gave investors a glimpse of its new product pipeline, which could help it stave off new entrants in its legacy sequencing business. While ...
Illumina pioneered Next Generation Sequencing (NGS) of DNA, a highly accurate and relatively affordable DNA sequencing technology. As market leader, Illumina quadruple its revenues in 10 years, ...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now ...
At ASHG, Illumina launches 5-base and shows exciting results from constellation, a breakthrough technology offering ...
SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped ...
At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands ...
5don MSN
Nature vs. nurture: Sequencing study quantifies genetic influence on human traits and diseases
Genome sequencing has been used to determine how much genes influence human characteristics including height and weight, and ...
StockStory.org on MSN
5 Revealing Analyst Questions From Illumina’s Q3 Earnings Call
Illumina’s third quarter results reflected stable year-over-year revenue and a notable beat on Wall Street’s profit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback